Skip to main content

Advertisement

SpringerLink
Log in

Management of the Primary Colorectal Cancer and Synchronous Liver Metastases

  • Colorectal Cancer Hepatic Metastases (MA Choti, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

In the last two decades, advances in liver surgery and systemic therapy have increased the scope and complexity of curative treatment of metastatic colorectal cancer. Synchronous liver metastasis represents a particularly challenging scenario where resection of the primary cancer and liver disease should be contemplated while still offering systemic therapy. Different treatment sequences have been proposed aiming to optimize long-term survival and decrease cumulative treatment-related morbidity. Safety and feasibility of colorectal-first, combined, and liver-first approaches have been demonstrated in selected subgroups of patients, but comparative analyses are undermined by the retrospective design and heterogeneity of available studies. The concept of a unifying ideal therapeutic approach does not seem realistic, and understanding the distinct principles of different strategies is paramount when planning surgical management of synchronous colorectal liver metastases. The role of systemic therapy before liver resection still requires better characterization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. McMillan DC, McArdle CS. Epidemiology of colorectal liver metastases. Surg Oncol. 16. Netherlands2007. p. 3-5.

  2. Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42:2212–21. England.

    Article  PubMed  Google Scholar 

  3. Haddad AJ, Bani Hani M, Pawlik TM, Cunningham SC. Colorectal liver metastases. Int J Surg Oncol. 2011;2011:285840.

    PubMed Central  PubMed  Google Scholar 

  4. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–9.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93(4):465–74.

    Article  CAS  PubMed  Google Scholar 

  6. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250:440–8.

    PubMed  Google Scholar 

  7. Mavros MN, de Jong M, Dogeas E, Hyder O, Pawlik TM. Impact of complications on long-term survival after resection of colorectal liver metastases. Br J Surg. 2013;100(5):711–8.

    Article  CAS  PubMed  Google Scholar 

  8. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–83.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Slesser AA, Simillis C, Goldin R, Brown G, Mudan S, Tekkis PP. A meta-analysis comparing simultaneous versus delayed resections in patients with synchronous colorectal liver metastases. Surg Oncol. 2013;22(1):36–47. Meta-analysis of 24 non-randomized studies demonstrating discrepant selection criteria, with higher metastatic burden in the staged-resection group.

    Article  CAS  PubMed  Google Scholar 

  10. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18. discussion 18-21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. D’Angelica MI, Kemeny NE. Metastatic colorectal cancer to the liver: involve the surgeon early and often. Ann Surg Oncol. 2015.

  12. Edge, S. B. et al. AJCC cancer staging manual 7th edn (Springer, 2010).

  13. Mekenkamp LJ, Koopman M, Teerenstra S, van Krieken JH, Mol L, Nagtegaal ID, et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer. 2010;103:159–64.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Wikman H, Vessella R, Pantel K. Cancer micrometastasis and tumour dormancy. APMIS. 2008;116:754–70.

    Article  CAS  PubMed  Google Scholar 

  15. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.

    Article  CAS  PubMed  Google Scholar 

  16. Wanebo HJ, Semoglou C, Attiyeh F, Stearns Jr MJ. Surgical management of patients with primary operable colorectal cancer and synchronous liver metastases. Am J Surg. 1978;135:81–5.

    Article  CAS  PubMed  Google Scholar 

  17. Cady B, McDermott WV. Major hepatic resection for metachronous metastases from colon cancer. Ann Surg. 1985;201(2):204–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Kelly ME, Spolverato G, Le GN, Mavros MN, Doyle F, Pawlik TM, et al. Synchronous colorectal liver metastasis: a network meta-analysis review comparing classical, combined, and liver-first surgical strategies. J Surg Oncol. 2015;111(3):341–51. Meta-analysis comparing colorectal-first, combined, and liver-first approaches with no clear surgical or survival outcome benefit in available retrospective studies.

    Article  CAS  PubMed  Google Scholar 

  19. Ohtani H, Tamamori Y, Arimoto Y, Nishiguchi Y, Maeda K, Hirakawa K. A meta-analysis of the short- and long-term results of randomized controlled trials that compared laparoscopy-assisted and open colectomy for colon cancer. J Cancer. 2012;3:49–57.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Ohtani H, Tamamori Y, Azuma T, Mori Y, Nishiguchi Y, Maeda K, et al. A meta-analysis of the short- and long-term results of randomized controlled trials that compared laparoscopy-assisted and conventional open surgery for rectal cancer. J Gastrointest Surg. 2011;15(8):1375–85.

    Article  PubMed  Google Scholar 

  21. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191:38–46.

    Article  CAS  PubMed  Google Scholar 

  22. Benzoni E, Lorenzin D, Baccarani U, Adani GL, Favero A, Cojutti A, et al. Resective surgery for liver tumor: a multivariate analysis of causes and risk factors linked to postoperative complications. Hepatobiliary Pancreat Dis Int. 2006;5:526–33.

    PubMed  Google Scholar 

  23. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236(4):397–406. discussion -7.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg. 2003;138:1198–206. discussion 206.

    Article  PubMed  Google Scholar 

  25. Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg. 2004;240:698–708. discussion -10.

    PubMed Central  PubMed  Google Scholar 

  26. Dimick JB, Cowan Jr JA, Knol JA, Upchurch Jr GR. Hepatic resection in the United States: indications, outcomes, and hospital procedural volumes from a nationally representative database. Arch Surg. 2003;138:185–91.

    Article  PubMed  Google Scholar 

  27. Capussotti L, Muratore A, Mulas MM, Massucco P, Aglietta M. Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. Br J Surg. 2006;93(8):1001–6.

    Article  CAS  PubMed  Google Scholar 

  28. Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribero D, Assumpcao L, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. 2007;14(12):3481–91.

    Article  PubMed  Google Scholar 

  29. Slesser AA, Chand M, Goldin R, Brown G, Tekkis PP, Mudan S. Outcomes of simultaneous resections for patients with synchronous colorectal liver metastases. Eur J Surg Oncol. 2013;39(12):1384–93.

    Article  CAS  PubMed  Google Scholar 

  30. Vassiliou I, Arkadopoulos N, Theodosopoulos T, Fragulidis G, Marinis A, Kondi-Paphiti A, et al. Surgical approaches of resectable synchronous colorectal liver metastases: timing considerations. World J Gastroenterol. 2007;13(9):1431–4.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Chua HK, Sondenaa K, Tsiotos GG, Larson DR, Wolff BG. Nagorney DM. Concurrent vs staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases Dis Colon Rectum. 2004;47(8):1310–6.

    Google Scholar 

  32. de Haas RJ, Adam R, Wicherts DA, Azoulay D, Bismuth H, Vibert E, et al. Comparison of simultaneous or delayed liver surgery for limited synchronous colorectal metastases. Br J Surg. 2010;97(8):1279–89.

    Article  PubMed  Google Scholar 

  33. Moug SJ, Smith D, Leen E, Roxburgh C, Horgan PG. Evidence for a synchronous operative approach in the treatment of colorectal cancer with hepatic metastases: a case matched study. Eur J Surg Oncol. 2009;36. Elsevier Ltd; 2010. p. 365-70.

  34. Slupski M, Wlodarczyk Z, Jasinski M, Masztalerz M, Tujakowski J. Outcomes of simultaneous and delayed resections of synchronous colorectal liver metastases. Can J Surg. 2009;52(6):E241–4.

    PubMed Central  PubMed  Google Scholar 

  35. Yan TD, Chu F, Black D, King DW, Morris DL. Synchronous resection of colorectal primary cancer and liver metastases. World J Surg. 2007;31(7):1496–501.

    Article  PubMed  Google Scholar 

  36. Taniai N, Yoshida H, Mamada Y, Matsumoto S, Mizuguchi Y, Suzuki H, et al. Outcome of surgical treatment of synchronous liver metastases from colorectal cancer. J Nippon Med Sch. 2006;73:82–8.

    Article  PubMed  Google Scholar 

  37. Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg. 2003;90(8):956–62.

    Article  CAS  PubMed  Google Scholar 

  38. Ejaz A, Semenov E, Spolverato G, Kim Y, Tanner D, Hundt J, et al. Synchronous primary colorectal and liver metastasis: impact of operative approach on clinical outcomes and hospital charges. HPB (Oxford). 2014;16(12):1117–26. Single-center retrospective study showing reduction in median length of hospitalization and total hospital charges with simultaneous resection, with perioperative and long-term outcomes comparable to staged resection.

    Article  Google Scholar 

  39. Thelen A, Jonas S, Benckert C, Spinelli A, Lopez-Hanninen E, Rudolph B, et al. Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. Int J Colorectal Dis. 2007;22(10):1269–76.

    Article  PubMed  Google Scholar 

  40. Tanaka K, Shimada H, Matsuo K, Nagano Y, Endo I, Sekido H, et al. Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases. Surgery. 2004;136:650–9.

    Article  PubMed  Google Scholar 

  41. Silberhumer GR, Paty PB, Temple LK, Araujo RL, Denton B, Gonen M, et al. Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. Am J Surg. 2014. Experience with combined-approach for rectal cancer with synchronous liver metastases demonstrating feasibility and safety in a high-volume center.

  42. Andres A, Toso C, Adam R, Barroso E, Hubert C, Capussotti L, et al. A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. Ann Surg. 2012;256:772–8. discussion 8-9.

    Article  PubMed  Google Scholar 

  43. Mayo SC, Pulitano C, Marques H, Lamelas J, Wolfgang CL, de Saussure W, et al. Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis. J Am Coll Surg. 2013;216(4):707–16. discussion 16-8. Large multi-institutional retrospective study demonstrating comparable surgical and survival outcomes with simultaneous and staged approaches.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010;210:934–41. Published by Elsevier Inc.; 2010.

    Article  PubMed  Google Scholar 

  45. van der Pool AE, de Wilt JH, Lalmahomed ZS, Eggermont AM, Ijzermans JN, Verhoef C. Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. Br J Surg. 2010;97(3):383–90.

    Article  PubMed  Google Scholar 

  46. Lam VW, Laurence JM, Pang T, Johnston E, Hollands MJ, Pleass HC, et al. A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. HPB (Oxford). 2014;16(2):101–8.

    Article  Google Scholar 

  47. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27:3379–84.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Nitzkorski JR, Farma JM, Watson JC, Siripurapu V, Zhu F, Matteotti RS, et al. Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection. Ann Surg Oncol. 2012;19(2):379–83.

    Article  PubMed  Google Scholar 

  49. Kim MS, Chung M, Ahn JB, Kim CW, Cho MS, Shin SJ, et al. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis. J Surg Oncol. 2014;110(2):214–21.

    Article  PubMed  Google Scholar 

  50. Manceau G, Brouquet A, Bachet JB, Penna C, El Hajjam M, Rougier P, et al. Response of liver metastases to preoperative radiochemotherapy in patients with locally advanced rectal cancer and resectable synchronous liver metastases. Surgery. 2013;154(3):528–35.

    Article  PubMed  Google Scholar 

  51. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773–80.

    Article  CAS  PubMed  Google Scholar 

  52. Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513–8.

    Article  CAS  PubMed  Google Scholar 

  53. Chan KM, Chiang JM, Lee CF, Yu MC, Lee WC, Chen JS, et al. Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment. World J Surg Oncol. 2011;9:174.

    Article  PubMed Central  PubMed  Google Scholar 

  54. House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 210. United States: 2010 American College of Surgeons. Published by Elsevier Inc; 2010. p. 744-52, 52-5.

  55. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–66.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Andres A, Majno PE, Morel P, Rubbia-Brandt L, Giostra E, Gervaz P, et al. Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score. Ann Surg Oncol. 2008;15(1):134–43.

    Article  PubMed  Google Scholar 

  57. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26:4906–11.

    Article  CAS  PubMed  Google Scholar 

  58. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007–16.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  59. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15. Updated follow up on the landmark EORTC study on perioperative FOLFOX4 for resectable colorectal liver metastases showing no significant overall survival benefit in the secondary outcome analysis.

    Article  CAS  PubMed  Google Scholar 

  60. Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, Humblet Y, Andre T, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007;25:5225–32.

    Article  CAS  PubMed  Google Scholar 

  61. Nikfarjam M, Shereef S, Kimchi ET, Gusani NJ, Jiang Y, Avella DM, et al. Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Ann Surg Oncol. 2009;16(7):1860–7.

    Article  PubMed  Google Scholar 

  62. Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg. 2009;16(2):137–44.

    Article  PubMed  Google Scholar 

  63. Utsumi H, Honma Y, Nagashima K, Iwasa S, Takashima A, Kato K, et al. Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal cancer. Anticancer Res. 2015;35:2255–61. International Institute of Anticancer Research (Dr. John G. Delinassios), 2015.

    CAS  PubMed  Google Scholar 

  64. D’Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol. 2007;14(2):759–65.

    Article  PubMed  Google Scholar 

  65. Neeff HP, Drognitz O, Klock A, Illerhaus G, Opitz OG, Hopt UT, et al. Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. Int J Colorectal Dis. 2012;27(5):635–45.

    Article  PubMed  Google Scholar 

  66. Yoshioka Y, Uehara K, Ebata T, Yokoyama Y, Mitsuma A, Ando Y, et al. Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. Surg Today. 2014;44(7):1300–6.

    Article  PubMed  Google Scholar 

  67. Lubezky N, Winograd E, Papoulas M, Lahat G, Shacham-Shmueli E, Geva R, et al. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases. J Gastrointest Surg. 2013;17(3):527–32.

    Article  PubMed  Google Scholar 

  68. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10(6):663–9.

    Article  CAS  PubMed  Google Scholar 

  69. Adam R, Avisar E, Ariche A, Giachetti S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001;8(4):347–53.

    Article  CAS  PubMed  Google Scholar 

  70. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311–9.

    Article  CAS  PubMed  Google Scholar 

  71. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57. discussion 57-8.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23:9243–9.

    Article  CAS  PubMed  Google Scholar 

  73. Baize N, Gerard B, Bleiberg H, Caroli-Bosc F, Berthier F, Legendre H, et al. Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. Gastroenterol Clin Biol. 2006;30:1349–53.

    Article  CAS  PubMed  Google Scholar 

  74. Nuzzo G, Giuliante F, Ardito F, Vellone M, Pozzo C, Cassano A, et al. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg. 2007;11(3):318–24.

    Article  PubMed  Google Scholar 

  75. Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2008;62(2):195–201.

    Article  CAS  PubMed  Google Scholar 

  76. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249:420–5.

    Article  PubMed  Google Scholar 

  77. D’Angelica MI, Correa-Gallego C, Paty PB, Cercek A, Gewirtz AN, Chou JF, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261(2):353–60.

    Article  PubMed  Google Scholar 

  78. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.

    Article  CAS  PubMed  Google Scholar 

  79. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17. Massachusetts Medical Society; 2009.

    Article  PubMed  Google Scholar 

  80. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663–71.

    Article  CAS  PubMed  Google Scholar 

  81. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47. England: 2010 Elsevier Ltd; 2010.

    Article  CAS  PubMed  Google Scholar 

  82. Petrelli F, Barni S. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis. 2012;27(8):997–1004.

    Article  CAS  PubMed  Google Scholar 

  83. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31:1931–8. United States.

    Article  CAS  PubMed  Google Scholar 

  84. Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007;25:5649–54.

    Article  PubMed  Google Scholar 

  85. Kemeny NE, Melendez FD, Capanu M, Paty PB, Fong Y, Schwartz LH, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27:3465–71.

    Article  PubMed Central  PubMed  Google Scholar 

  86. Karanicolas PJ, Metrakos P, Chan K, Asmis T, Chen E, Kingham TP, et al. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. Curr Oncol. 2014;21:e129–36.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Alexsander K. Bressan declares that he has no conflict of interest. Elijah Dixon has received compensation from Roche for serving on speaker’s bureau.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Surgery and Oncology, Foothills Medical Centre and the University of Calgary, 1403 – 29 Street NW, Calgary, Alberta, T2N 2T9, Canada

    Alexsander K. Bressan & Elijah Dixon

Authors
  1. Alexsander K. Bressan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elijah Dixon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elijah Dixon.

Additional information

This article is part of the Topical Collection on Colorectal Cancer Hepatic Metastases

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bressan, A.K., Dixon, E. Management of the Primary Colorectal Cancer and Synchronous Liver Metastases. Curr Colorectal Cancer Rep 11, 178–186 (2015). https://doi.org/10.1007/s11888-015-0273-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-015-0273-6

Keywords

Search

Navigation